Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1211.00
-¥69.00(-5.70%)
At close: 4:00 PM EDT
¥1211.00
-¥69.00(-5.70%)
Day’s Range― - ―
52-Week Range¥1,067.00 - ¥1,725.00
Previous CloseN/A
Volume266.10K
Average Volume (3M)127.03K
Market Cap
¥60.11B
Enterprise Value¥72.70K
Total Cash (Recent Filing)¥15.08B
Total Debt (Recent Filing)¥23.79B
Price to Earnings (P/E)30.2
Beta0.50
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.99%
Share Statistics
EPS (TTM)60.01
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)0.66
Price to Sales (P/S)0.75
P/FCF Ratio37.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)28.85
Revenue Forecast (FY)¥123.03B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageKYORIN's low leverage and steadily growing equity give the company durable financial flexibility to fund R&D, absorb reimbursement headwinds, and pursue partnerships. A debt-to-equity near 0.17 reduces refinancing and interest risk, supporting multi‑quarter strategic investments without overreliance on external financing.
Diversified Revenue Streams: Sales + LicensingA core prescription drug business paired with licensing, milestones, and royalties provides complementary, durable revenue engines. Branded product sales deliver recurring cash while licensing monetizes R&D beyond domestic commercialization, reducing single-channel dependency and enhancing long‑term revenue resilience.
Improved Operating Cash Flow And Positive FCF In FY2026The operating cash flow recovery and return to positive free cash flow support internal funding for R&D, commercial activities, and shareholder returns. While prior years were weak, the FY2026 cash rebound demonstrates improved cash conversion capacity that can sustain medium‑term operations and strategic initiatives.
Bears Say
Material Margin DeteriorationSignificant margin compression in FY2026 suggests pressure from pricing, cost inflation, or adverse product mix. Lower gross and net margins materially reduce return on equity and earnings power, constraining reinvestment into R&D, commercialization of new indications, and long‑term margin recovery unless structural drivers are addressed.
Volatile Free Cash Flow And Uneven Cash ConversionHighly swingy free cash flow complicates multi‑year planning for clinical programs, marketing launches, and dividend policy. Inconsistent cash conversion increases reliance on timing of licensing milestones or external financing to bridge funding needs, raising execution risk for sustained growth initiatives over the next several quarters.
Revenue Sensitivity And Concentrated Product RiskKYORIN's revenue concentration in core respiratory and infectious disease brands, together with sensitivity to Japan's reimbursement/pricing mechanism, creates structural vulnerability. The FY2026 revenue decline (~4.3% YoY) underscores exposure to price revisions, generics, or market‑share loss that could persist without pipeline success or portfolio diversification.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1067.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥60.11B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 96 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on Jul 30, 2026. The company reported ¥14.35 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 4.99%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of ¥14.35 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―